Korea Biomedical Review

Hanmi Pharmaceuticals presented 3 posters on the results of its research on #MAT2A inhibitor (HM100760), a selective HER2 exon 20 insertion mutation inhibitor, and #SOS1 inhibitor (HM99462) at the EORTC-NCI-AACR 2024, an international cancer conference held in #Barcelona, Spain, from Wednesday to Friday last week (local time). https://lnkd.in/g4RcMi93

Mediwhale wins 1st place in MICCAI’s medical AI competition #MICCAI Society https://lnkd.in/g-Y4HgWg

As the U.S. presidential election on Nov. 5 approaches, industry experts predict significant changes in the global biotechnology landscape, regardless of whether Democratic candidate Kamala Harris or Republican Donald Trump prevails in what polls suggest is a tight race. According to a recent report from the Korea Institute for Industrial Economics & Trade (KIET), both candidates are expected to pursue policies that would restructure biotech supply chains around U.S. interests, though their approaches differ in scope and methodology.

Neurophet announced an exclusive sales agreement with Beijing LADO Technology, granting market entry into China for its PET image analysis software, #NeurophetSCALEPET, and planning a joint venture. https://lnkd.in/gr5KTQnq

FutureChem, a Korea-based radiopharmaceutical company, presented interim results from its phase 2 clinical trial for FC705, a prostate cancer treatment radiopharmaceutical candidate, at the Asia Pacific Prostate Society (APPS) Conference in Hawaii, running from last Saturday to Friday.

At a press conference marking #WorldPsoriasisDay, Chul Hwan Bang of the The Catholic University of Korea said that Korea has updated its #psoriasis severity criteria to allow for greater flexibility, enabling patients with a #PASI score between 5 and 10, along with significant localized psoriasis, to qualify for moderate-to-severe classification. https://lnkd.in/grpvPS_j

NEXTBIOMEDICAL, a local medical solution company, has submitted documentation to the U.S. FDA to expand the indication for its endoscopic hemostatic agent, Nexpowder, to include preventive use for lower gastrointestinal (GI) tract bleeding.

A consortium led by Macrogen Inc., a Korean genomics company, has been chosen as the preferred negotiator for the genome sequencing contract in Korea's National Integrated Bio Big Data Project. The consortium, which includes DNA Link, Theragen Bio, and @CG Biotech, is set to lead a project commissioned by the Korea Research Institute of Bioscience and Biotechnology (KRIBB) and funded by the Ministry of Health and Welfare, Ministry of Science and ICT, Ministry of Trade, Industry and Energy, and the Korea Disease Control and Prevention Agency (KDCA). 출처 : KBR(https://lnkd.in/gK7z_98p)

A recent study conducted by researchers from Asan Medical Center (AMC) indicates that stem cells could offer a novel treatment approach for underactive bladders in diabetic patients, a condition that has historically posed management challenges. https://lnkd.in/gTTMe-UF

NGeneBio Co., Ltd. announced the launch of Korea's first large-scale gene fusion diagnostic panel for solid tumors, called "ONCOaccuPanel RNA," designed to precisely diagnose gene fusion mutations in cancer patients.